mic panels (JMI Laboratories)
90
Structured Review
JMI Laboratories
mic panels
Mic Panels, supplied by JMI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mic+panels/mic+panels/pm40558134-91-2-11
Average 90 stars, based on 1 article reviews
Mic Panels, supplied by JMI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mic+panels/mic+panels/pm40558134-91-2-11
Average 90 stars, based on 1 article reviews
mic panels - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020). Article Snippet: Ceftaroline and comparators were tested against 9,268 Staphylococcus aureus isolates from 33 United States hospitals (2018 2020).. Ceftaroline (MIC50/90, 0.25/1 mg/L) susceptibility ranged from 95.4% (pneumonia) to 98.5% (skin and skin structure) and was 97.2% overall.. Ceftaroline retained potent and broad-spectrum activity against methicillin-resistant isolates, with a 93.4% overall susceptibility. Article Title: Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). Article Snippet: Methods: A total of 102 995 bacterial isolates were consecutively collected (one per patient) in 1997–2016 from 258 medical centres in North America (n"44 999; 113 centres), Europe (n"30 988; 61 centres from 22 nations), the Asia-Pacific region (APAC; n"16 503; 67 centres from 12 nations) and Latin America (n"10 505; 17 centres from 7 nations).. Organisms were isolated from respiratory tract specimens and tested for susceptibility by broth microdilution methods in a central laboratory. Article Title: Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019-2023). Article Snippet: Validated frozen Article Title: Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. Article Snippet: Frozen-form MIC panels were prepared at Article Title: 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms. Article Snippet: Objectives: Lefamulin (Xenleta), a pleuromutilin antibiotic, was approved for the oral and IV treatment of community-acquired bacterial pneumonia (CABP) in adults in 2019/2020.. This study evaluated the in vitro activity of lefamulin and comparators against 19 584 unique bacterial isolates collected from patients with communityacquired respiratory tract infections and hospitalized patients with pneumonia within the global SENTRY Antimicrobial Surveillance Program during 2015–21. Article Title: Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide. Article Snippet: Methods: A total of 891 isolates were collected by the SENTRY Antimicrobial Surveillance Program from 134 medical centres in Europe (n = 424; 41 centres in 18 nations), the USA (n = 411 isolates from 67 centres), the Asia-Pacific region (n = 24; 15 centres in 6 nations) and Latin America (n = 32; 11 centres in 9 nations) and included 558 Enterobacterales, 310 non-fermenters and 23 fastidious organisms.. Susceptibility testing was performed using the reference broth microdilution method and the medium was supplemented with 0.002% polysorbate-80 for testing POL7306.. Resistant subsets were characterized by WGS. Concentration Assay:Article Title: Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America. Article Snippet: Objectives: Ceftaroline fosamil is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).. This study evaluated the frequency and antimicrobial susceptibility of organisms isolated from patients hospitalised with community-acquired (CA) SSSI in Europe, the Asia-Pacific region (APAC) and Latin America (LATAM).. Methods: Isolates (n = 5120) were consecutively collected from patients hospitalised with CA-SSSI in 2014–2016 from 63 medical centres in 41 nations, stratified as Western Europe (20 centres/10 nations), Eastern Europe and the Mediterranean region (E-EUR; 16 centres/12 nations), APAC (16 centres/10 nations) and LATAM (11 centres/9 nations). Article Title: Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. Article Snippet: Species identification was confirmed by standard biochemical tests and using the MALDI Biotyper (Bruker Daltonics, Billerica, MA, USA) according to the manufacturer’s instructions, when necessary. .. Broth microdilution testing, conducted according to CLSI methods, determined the antimicrobial susceptibility of ceftolozane/tazobactam (inhibitor at fixed concentration of 4 mg/L) and comparator agents.8 |